News GentiBio
August 5, 2020

GentiBio Joins Cell Therapy Chase With $20M and New Treg Technology

One of the challenges facing cell therapy developers is collecting enough cells to produce a viable treatment. It’s a particularly pronounced problem for therapies employing regulatory T cells (Tregs). Some biotech companies are developing Treg cell therapies from a patient’s own Tregs, which are scarce. GentiBio makes its Treg therapeutic candidates from an entirely different type of immune cell.

Read more on Geekwire